Evidence map›Paper›PMID 26669428›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Cocaine Hydrolase Gene Transfer Demonstrates Cardiac Safety and Efficacy against Cocaine-Induced QT Prolongation in Mice.

Vishakantha Murthy, Santiago Reyes, Liyi Geng, Yang Gao, Stephen Brimijoin

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vishakantha MurthyDepartment of Molecular Pharmacology and Experimental Therapeutics, Robert and Arlene Kogod Center on Aging (V.M., L.G., Y.G., S.B.), and Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (S.R.), Mayo Clinic, Rochester, Minnesota murthy.vishakantha@mayo.edu.
Santiago ReyesDepartment of Molecular Pharmacology and Experimental Therapeutics, Robert and Arlene Kogod Center on Aging (V.M., L.G., Y.G., S.B.), and Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (S.R.), Mayo Clinic, Rochester, Minnesota.
Liyi GengDepartment of Molecular Pharmacology and Experimental Therapeutics, Robert and Arlene Kogod Center on Aging (V.M., L.G., Y.G., S.B.), and Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (S.R.), Mayo Clinic, Rochester, Minnesota.
Yang GaoDepartment of Molecular Pharmacology and Experimental Therapeutics, Robert and Arlene Kogod Center on Aging (V.M., L.G., Y.G., S.B.), and Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (S.R.), Mayo Clinic, Rochester, Minnesota.
Stephen BrimijoinDepartment of Molecular Pharmacology and Experimental Therapeutics, Robert and Arlene Kogod Center on Aging (V.M., L.G., Y.G., S.B.), and Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (S.R.), Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · US

Funding

Cocaine hydrolase gene therapy for cocaine abuse (DPI)DP1DA031340 · NIDA · MAYO CLINIC ROCHESTER · PI BRIMIJOIN, WILLIAM STEPHEN · 2010 to 2014
$3.9M
Development of a Human Hydrolase to Treat Cocaine Abuse and Overdose:Rat ModelsR01DA023979 · NIDA · MAYO CLINIC ROCHESTER · PI BRIMIJOIN, WILLIAM STEPHEN · 2007 to 2011
$2.3M
NIDA NIH HHS D1DA31340NIDA NIH HHS DP1 DA031340NIDA NIH HHS R01 DA023979NIDA NIH HHS R01DA23979
6 · The paper itself

Abstract

Cocaine addiction is associated with devastating medical consequences, including cardiotoxicity and risk-conferring prolongation of the QT interval. Viral gene transfer of cocaine hydrolase engineered from butyrylcholinesterase offers therapeutic promise for treatment-seeking drug users. Although previous preclinical studies have demonstrated benefits of this strategy without signs of toxicity, the specific cardiac safety and efficacy of engineered butyrylcholinesterase viral delivery remains unknown. Here, telemetric recording of electrocardiograms from awake, unrestrained mice receiving a course of moderately large cocaine doses (30 mg/kg, twice daily for 3 weeks) revealed protection against a 2-fold prolongation of the QT interval conferred by pretreatment with cocaine hydrolase vector. By itself, this prophylactic treatment did not affect QT interval duration or cardiac structure, demonstrating that viral delivery of cocaine hydrolase has no intrinsic cardiac toxicity and, on the contrary, actively protects against cocaine-induced QT prolongation.

Indexed as

Gene Transfer TechniquesAnimalsCocaineHydrolasesLong QT SyndromeMaleMiceMice, Inbred BALB CTreatment OutcomeCocaineHydrolases

Identifiers

PMID26669428
PMCPMC4767396
OpenAlexW2220833290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.